Business Combinations - Schedule of Revenue Growth that may be Anticipated (Details) - Avadel Pharmaceuticals Plc [Member] - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2026 |
Sep. 30, 2025 |
Sep. 30, 2026 |
Sep. 30, 2025 |
|
| Business Combination, Pro Forma Information [Line Items] | ||||
| Revenues | $ 480,132 | $ 471,652 | $ 1,401,881 | $ 1,289,459 |
| Net income (loss) | $ 37,619 | $ 26,540 | $ 38,096 | $ (70,688) |
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount, after tax, of pro forma income (loss) of combined entity as if acquisition date of business combination occurred as of beginning of period. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of pro forma revenue of combined entity as if acquisition date of business combination occurred as of beginning of period. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Details
|